The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.